A study conducted by Avalere Health shows a considerable drop in cancer screening, diagnosis, and treatment for American seniors and Medicare beneficiaries in 2020.
A clinical guideline from the American Society for Radiation Oncology provides guidance for physicians who use radiation therapy to treat patients with locally advanced rectal cancer.
Data from the NCI-MATCH precision medicine trial established a new benchmark for next-generation sequencing in clinical trials.
Miami Cancer Institute researchers found that the overall median survival for patients with brain metastases has improved over time.
Napo Pharmaceuticals Inc., a wholly owned subsidiary of Jaguar Health Inc., has initiated its pivotal phase III clinical trial of crofelemer (Mytesi) for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy.
The phase II clinical study EV-201 evaluating the antibody-drug conjugate Padcev (enfortumab vedotinejfv) for treatment of urothelial cancer demonstrated a 52% overall response rate in the second cohort.
Researchers at the UCLA Jonsson Comprehensive Cancer Center have found that a virus-mimicking drug, BO-112, may also make certain stealthy melanoma tumors visible to the immune system, allowing them to be better targeted by immunotherapy.
In a new clinical trial, City of Hope is investigating a treatment for cancer patients with COVID-19 by repurposing leflunomide, an anti-inflammatory drug for rheumatoid arthritis, which is inexpensive and has few serious side effects.
A novel cancer therapy studied and developed at the Medical College of Wisconsin with promising clinical outcomes is leading to a larger phase II trial to improve on the current standard of care.
Researchers at MD Anderson Cancer Center have identified molecular and cellular characteristics of anti-CD19 CAR T cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and develop side effects.